FRANKFURT, Sept 14 (Reuters) - BioNTech said on Monday that a late-stage trial showed its drug candidate gotistobart led to a ...
Shares rose after strong clinical data strengthened the case for its $10.6 billion Nuvalent acquisition and broader push to rebuild oncology around lung cancer.
The clinical-stage biopharmaceutical company said that a twice-daily 4.5mg dose of AGMB-447, a treatment for idiopathic pulmonary fibrosis, had a more than 50% reduction of pSMAD3 proteins in lung ...
Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced ...
In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went ...
Jazz Pharmaceuticals (NasdaqGS:JAZZ) is assessing new trials of newly approved cancer drug Ziihera beyond gastroesophageal ...
GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an ...
BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place ...
In July 2025, the Lung Association, with support from the Feldman Family Foundation, launched the Lung Health Navigator ...
Detecting lung cancer early is critical to a patient's survival, but how early is early enough? Florida International ...
BioNTech SE said its experimental drug gotistobart nearly doubled the median survival of patients with an aggressive form of ...
Lung cancer is the leading cause of cancer death in the United States, claiming more than 125,000 lives each year. There is a quick, painless screening test that can detect lung cancer before symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results